Performance Status in Cancer: Not Broken, But Time for an Upgrade?
作者信息
Scott Jessica M, Stene Guro, Edvardsen Elisabeth, Jones Lee W
机构信息
Memorial Sloan Kettering Cancer Center, New York, NY.
Weill Cornell Medical College, New York, NY.
出版信息
J Clin Oncol. 2020 Sep 1;38(25):2824-2829. doi: 10.1200/JCO.20.00721. Epub 2020 Jun 25.
Abstract
摘要
相似文献
1
Performance Status in Cancer: Not Broken, But Time for an Upgrade?
J Clin Oncol. 2020 Sep 1;38(25):2824-2829. doi: 10.1200/JCO.20.00721. Epub 2020 Jun 25.
2
Measure Me, Don't Judge Me: Patients as Objective Contributors to Performance Status Measurement.
JCO Clin Cancer Inform. 2018 Dec;2:1-4. doi: 10.1200/CCI.18.00029.
3
Interconversion of three measures of performance status: an empirical analysis.
Eur J Cancer. 2010 Dec;46(18):3175-83. doi: 10.1016/j.ejca.2010.06.126. Epub 2010 Jul 30.
4
Karnofsky performance status and assessment of global health status.
J Acquir Immune Defic Syndr Hum Retrovirol. 1996 Nov 1;13(3):294-5. doi: 10.1097/00042560-199611010-00013.
5
The Palliative Performance Scale #125.
J Palliat Med. 2006 Aug;9(4):994. doi: 10.1089/jpm.2006.9.994.
6
Neoplastic meningitis-related prognostic significance of the Karnofsky performance status.
Arch Neurol. 2009 Jan;66(1):74-8. doi: 10.1001/archneurol.2008.506.
7
Use of the Palliative Performance Scale in survival prediction for terminally ill patients in Western Newfoundland, Canada.
J Palliat Care. 2008 Winter;24(4):282-4.
8
JAMA Oncology Patient Page. Performance Status in Patients With Cancer.
JAMA Oncol. 2015 Oct;1(7):998. doi: 10.1001/jamaoncol.2015.3113.
9
Karnofsky Performance Scale (KPS) or Physical Performance Test (PPT)? That is the question.
Crit Rev Oncol Hematol. 2011 Feb;77(2):142-7. doi: 10.1016/j.critrevonc.2010.01.015. Epub 2010 Feb 24.
10
Prognostic value of performance status assessed by patients themselves, nurses, and oncologists in advanced non-small cell lung cancer.
Br J Cancer. 2001 Nov 30;85(11):1634-9. doi: 10.1054/bjoc.2001.2162.
引用本文的文献
1
Addressing the evidence gap: exploratory insights into dual challenges of mild cognitive impairment and hematologic cancer in older adults through mixed methods and social listening study.
Eur Geriatr Med. 2025 Sep 16. doi: 10.1007/s41999-025-01292-y.
2
Eligibility criteria in phase 3 randomized controlled trials in gastric cancer.
Gastric Cancer. 2025 Sep 11. doi: 10.1007/s10120-025-01653-3.
3
Measures of physical functioning in adults with brain tumor associated with functional outcomes: A scoping review.
Neurooncol Pract. 2025 Mar 26;12(4):571-584. doi: 10.1093/nop/npaf036. eCollection 2025 Aug.
4
Predicting Tolerance to Anthracycline Chemotherapy Using Electrocardiogram-Based Artificial Intelligence in Sarcoma.
Mayo Clin Proc Digit Health. 2025 Jul 4;3(3):100247. doi: 10.1016/j.mcpdig.2025.100247. eCollection 2025 Sep.
5
Performance status eligibility requirements and enrollment characteristics in cancer clinical trials leading to US Food and Drug Administration drugs approval (2009-2023).
Eur J Cancer. 2025 Jul 25;225:115589. doi: 10.1016/j.ejca.2025.115589. Epub 2025 Jun 26.
6
Exercise Testing Characteristics, Safety, and Quality in Patients with Cancer: A Systematic Review.
Mayo Clin Proc Innov Qual Outcomes. 2025 Jun 11;9(4):100628. doi: 10.1016/j.mayocpiqo.2025.100628. eCollection 2025 Aug.
7
Navigating challenging patient factors in systemic therapy for head and neck cancer.
Oncologist. 2025 May 8;30(5). doi: 10.1093/oncolo/oyaf035.
8
Does frailty modulate the predictive value of performance status in older adults living with cancer?
Res Sq. 2025 Apr 15:rs.3.rs-6285336. doi: 10.21203/rs.3.rs-6285336/v1.
9
Predictive and Prognostic Significance of Patient-Reported Outcomes for Survival and Adverse Events in Daratumumab-Treated Multiple Myeloma.
Eur J Haematol. 2025 Jun;114(6):1020-1031. doi: 10.1111/ejh.14410. Epub 2025 Mar 14.
10
Association of pre-existing cardiovascular disease with administration of fluoropyrimidine chemotherapy in patients with gastrointestinal malignancies.
BMJ Oncol. 2024 Aug 8;3(1):e000323. doi: 10.1136/bmjonc-2024-000323. eCollection 2024.
本文引用的文献
1
Association of Daily Step Count and Step Intensity With Mortality Among US Adults.
JAMA. 2020 Mar 24;323(12):1151-1160. doi: 10.1001/jama.2020.1382.
2
Association of post-diagnosis cardiorespiratory fitness with cause-specific mortality in cancer.
Eur Heart J Qual Care Clin Outcomes. 2020 Oct 1;6(4):315-322. doi: 10.1093/ehjqcco/qcaa015.
3
Estimated Research and Development Investment Needed to Bring a New Medicine to Market, 2009-2018.
JAMA. 2020 Mar 3;323(9):844-853. doi: 10.1001/jama.2020.1166.
4
Inter-rater reliability in performance status assessment among healthcare professionals: an updated systematic review and meta-analysis.
Support Care Cancer. 2020 May;28(5):2071-2078. doi: 10.1007/s00520-019-05261-7. Epub 2020 Jan 3.
5
Overall Survival with Osimertinib in Untreated, -Mutated Advanced NSCLC.
N Engl J Med. 2020 Jan 2;382(1):41-50. doi: 10.1056/NEJMoa1913662. Epub 2019 Nov 21.
6
Multisystem Toxicity in Cancer: Lessons from NASA's Countermeasures Program.
Cell. 2019 Nov 14;179(5):1003-1009. doi: 10.1016/j.cell.2019.10.024.
7
Need for Multidisciplinary Research and Data-Driven Guidelines for the Cardiovascular Care of Patients With Cancer.
JAMA. 2019 Nov 12;322(18):1775-1776. doi: 10.1001/jama.2019.17415.
8
Innovation and Access at the Mercy of Payment Policy: The Future of Chimeric Antigen Receptor Therapies.
J Clin Oncol. 2020 Feb 10;38(5):384-387. doi: 10.1200/JCO.19.01691. Epub 2019 Nov 1.
9
Using Smartphones to Capture Novel Recovery Metrics After Cancer Surgery.
JAMA Surg. 2020 Feb 1;155(2):123-129. doi: 10.1001/jamasurg.2019.4702.
10
Wearable activity monitors to assess performance status and predict clinical outcomes in advanced cancer patients.
NPJ Digit Med. 2018 Jul 5;1:27. doi: 10.1038/s41746-018-0032-6. eCollection 2018.
Zotero 插件